Anti-factor Xa levels in obese patients receiving enoxaparin for treatment and prophylaxis indications

Linda Tahaineh,1 Sahar M Edaily,1 Shadi F Gharaibeh2 1Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology (JUST), Irbid, Jordan; 2Department of Pharmaceutical Sciences, Faculty of Pharmacy, Jerash University, Jerash, Jordan Objectives: To evaluate the de...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tahaineh L, Edaily SM, Gharaibeh SF
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	Anti-factor Xa anticoagulation enoxaparin obesity Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/df87d9ab82574242b6cbd410b1584d3a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:df87d9ab82574242b6cbd410b1584d3a
record_format	dspace
spelling	oai:doaj.org-article:df87d9ab82574242b6cbd410b1584d3a2021-12-02T00:23:13ZAnti-factor Xa levels in obese patients receiving enoxaparin for treatment and prophylaxis indications1179-1438https://doaj.org/article/df87d9ab82574242b6cbd410b1584d3a2018-05-01T00:00:00Zhttps://www.dovepress.com/anti-factor-xa-levels-in-obese-patients-receiving-enoxaparin-for-treat-peer-reviewed-article-CPAAhttps://doaj.org/toc/1179-1438Linda Tahaineh,1 Sahar M Edaily,1 Shadi F Gharaibeh2 1Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology (JUST), Irbid, Jordan; 2Department of Pharmaceutical Sciences, Faculty of Pharmacy, Jerash University, Jerash, Jordan Objectives: To evaluate the degree of anticoagulation achieved with different enoxaparin dosing regimens used in obese and morbidly obese patients in a hospital setting in Jordan.Methods: All obese adult patients who were prescribed enoxaparin for various indications were invited to participate in the study. The anti-factor Xa (anti-Xa) level was checked once after 4–6 hours of the third or fourth dose of enoxaparin (at steady state). Patients were followed daily to evaluate drug efficacy and safety through their hospital course.Results: Enoxaparin daily dose used for prophylaxis indications ranged from 0.3 to 0.85 mg/kg and from 0.31 to 2.25 mg/kg in case of certain treatment indications. Most participants who received enoxaparin for treatment indications (76.9%) were on capping dosing regimens, which was <1 mg/kg twice daily. On the other hand, most patients (88.5%) who received enoxaparin for prophylaxis indications were on a fixed 40 mg/d dose. Among the 52 patients who completed the study, 19 patients (36.5%) had therapeutic anti-Xa levels. The results showed no statistically significant associations between regimens that were used and achieving therapeutic anti-Xa level (p>0.05). No bleeding events or thrombocytopenia were noticed, and there was one case of recurrent thrombosis.Conclusion: Enoxaparin dosing regimens that were used for obese patients varied based on prescribing physicians. Regardless of the regimen used, the majority of participants had nontherapeutic anti-Xa. Individualized dosing regimens based on anti-Xa levels are warranted for obese patients on enoxaparin. Keywords: anti-factor Xa, anticoagulation, enoxaparin, obesityTahaineh LEdaily SMGharaibeh SFDove Medical PressarticleAnti-factor XaanticoagulationenoxaparinobesityTherapeutics. PharmacologyRM1-950ENClinical Pharmacology: Advances and Applications, Vol Volume 10, Pp 63-70 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Anti-factor Xa anticoagulation enoxaparin obesity Therapeutics. Pharmacology RM1-950
spellingShingle	Anti-factor Xa anticoagulation enoxaparin obesity Therapeutics. Pharmacology RM1-950 Tahaineh L Edaily SM Gharaibeh SF Anti-factor Xa levels in obese patients receiving enoxaparin for treatment and prophylaxis indications
description	Linda Tahaineh,1 Sahar M Edaily,1 Shadi F Gharaibeh2 1Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology (JUST), Irbid, Jordan; 2Department of Pharmaceutical Sciences, Faculty of Pharmacy, Jerash University, Jerash, Jordan Objectives: To evaluate the degree of anticoagulation achieved with different enoxaparin dosing regimens used in obese and morbidly obese patients in a hospital setting in Jordan.Methods: All obese adult patients who were prescribed enoxaparin for various indications were invited to participate in the study. The anti-factor Xa (anti-Xa) level was checked once after 4–6 hours of the third or fourth dose of enoxaparin (at steady state). Patients were followed daily to evaluate drug efficacy and safety through their hospital course.Results: Enoxaparin daily dose used for prophylaxis indications ranged from 0.3 to 0.85 mg/kg and from 0.31 to 2.25 mg/kg in case of certain treatment indications. Most participants who received enoxaparin for treatment indications (76.9%) were on capping dosing regimens, which was <1 mg/kg twice daily. On the other hand, most patients (88.5%) who received enoxaparin for prophylaxis indications were on a fixed 40 mg/d dose. Among the 52 patients who completed the study, 19 patients (36.5%) had therapeutic anti-Xa levels. The results showed no statistically significant associations between regimens that were used and achieving therapeutic anti-Xa level (p>0.05). No bleeding events or thrombocytopenia were noticed, and there was one case of recurrent thrombosis.Conclusion: Enoxaparin dosing regimens that were used for obese patients varied based on prescribing physicians. Regardless of the regimen used, the majority of participants had nontherapeutic anti-Xa. Individualized dosing regimens based on anti-Xa levels are warranted for obese patients on enoxaparin. Keywords: anti-factor Xa, anticoagulation, enoxaparin, obesity
format	article
author	Tahaineh L Edaily SM Gharaibeh SF
author_facet	Tahaineh L Edaily SM Gharaibeh SF
author_sort	Tahaineh L
title	Anti-factor Xa levels in obese patients receiving enoxaparin for treatment and prophylaxis indications
title_short	Anti-factor Xa levels in obese patients receiving enoxaparin for treatment and prophylaxis indications
title_full	Anti-factor Xa levels in obese patients receiving enoxaparin for treatment and prophylaxis indications
title_fullStr	Anti-factor Xa levels in obese patients receiving enoxaparin for treatment and prophylaxis indications
title_full_unstemmed	Anti-factor Xa levels in obese patients receiving enoxaparin for treatment and prophylaxis indications
title_sort	anti-factor xa levels in obese patients receiving enoxaparin for treatment and prophylaxis indications
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/df87d9ab82574242b6cbd410b1584d3a
work_keys_str_mv	AT tahainehl antifactorxalevelsinobesepatientsreceivingenoxaparinfortreatmentandprophylaxisindications AT edailysm antifactorxalevelsinobesepatientsreceivingenoxaparinfortreatmentandprophylaxisindications AT gharaibehsf antifactorxalevelsinobesepatientsreceivingenoxaparinfortreatmentandprophylaxisindications
_version_	1718403772458205184

Anti-factor Xa levels in obese patients receiving enoxaparin for treatment and prophylaxis indications

Ejemplares similares